Precision BioSciences, Inc.

About Precision BioSciences, Inc.

Precision BioSciences is a biotechnology company focused on advancing science and curing genetic diseases through its proprietary ARCUS genome editing technology. Their mission is to develop a new class of medicines to overcome and potentially cure hard-to-treat conditions, including rare genetic diseases, with the goal of restoring hope to patients.

Products & Services

ARCUS Genome Editing:A proprietary genome editing platform using sequence-specific DNA-cutting enzymes to insert, remove, or repair DNA in living cells and tissues, aimed at treating rare genetic diseases.

PBGENE-HBV:A gene editing therapy targeting Hepatitis B Virus (HBV) with a dual mechanism to eliminate cccDNA and inactivate integrated HBV DNA, currently in clinical trials.

PBGENE-DMD:A gene editing approach for the treatment of Duchenne Muscular Dystrophy (DMD), with preclinical data supporting advancement towards clinical stages.

PBGENE-PMM:A potential therapy for Primary Mitochondrial Myopathy, with plans to advance towards IND or CTA in 2025.

Azer-Cel:An allogeneic CAR T cell therapy licensed to partners for applications in cancer and autoimmune diseases.

Specialties

Genome Editing Gene Therapy CAR T Cell Therapy Rare Genetic Diseases Hepatitis B Treatment Duchenne Muscular Dystrophy Treatment Mitochondrial Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2025-11-10 FD: 2025-11-10	10 investors
2	RT: Convertible Note T: - FT: Convertible Note	A: 13000000 MR: - FA: $13 million FAN: 13000000	D: 2024-08-30 FD: 2024-08-30	1 investors
3	RT: Private Placement T: - FT: Private Placement	A: 300000 MR: - FA: 300,000 FAN: 300000	D: 2024-05-08 FD: 2024-05-08	1 investors
4	RT: Public Offering T: - FT: Public Offering	A: 40000000 MR: - FA: $40.0 million FAN: 40000000	D: 2024-03-01 FD: 2024-03-01	4 investors
5	RT: Equity and Cash Investment T: - FT: Equity and Cash Investment	A: 7500000 MR: - FA: 7.5 million FAN: 7500000	D: 2024-02-12 FD: 2024-02-12	1 investors

Underwritten Offering Latest

2025-11-10

$75.0M

10 investors (Pro only)

Convertible Note 2024-08-30

$13.0M

Private Placement 2024-05-08

$300K

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael Amoroso

President & Chief Executive Officer

J

Jeff Smith

Co-Founder, Chief Research Officer

C

Cindy Atwell

Chief Development and Business Officer

A

Alex Kelly

Chief Financial Officer

D

Dario Scimeca

General Counsel

C

Cassie Gorsuch

Chief Scientific Officer

View 28 more team members with Pro

Unlock Full Team Directory

Recent News